Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation

@article{Sahm2011ImmunohistochemicalAO,
  title={Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation},
  author={Felix Sahm and David Capper and Jochen Meyer and Christian Hartmann and Esther Herpel and Mindaugas Andrulis and Gunhild Mechtersheimer and Iver Petersen and Werner Paulus and Andreas von Deimling},
  journal={Histopathology},
  year={2011},
  volume={58}
}
Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, Mechtersheimer G, Petersen I, Paulus W & von Deimling A
(2011) Histopathology 58, 1167–1172
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation 
View on Wiley
hal.archives-ouvertes.fr
14 Citations
Background Citations
4

14 Citations

Citation Type

Citation Type

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
TLDR
IHC using the VE1 clone and FLEX linker is a specific method for the Detection of BRAF V600E and may be an alternative to molecular-biologic techniques for the detection of mutations in ovarian serous borderline tumors.
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
  • Jun Lu, Yang Zou, +5 authors Yong-Gang Yao
  • Biology, Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2014
TLDR
The negative results of this study suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC, and some previous reports of the absence of IDH 1 p.
IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas
TLDR
Napsin A expression in SH seems to further support the most recent and accepted hypothesis that this benign and polymorphic pulmonary tumour differentiates towards the peripheral respiratory epithelium.
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants
TLDR
In one of the most challenging differential diagnoses, IDH1 positivity could provide strong support for glioblastoma with oligodendroglial component, while essentially excluding small cell gliOBlastoma.
Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas
TLDR
This study demonstrated that the somatic mutations of PIK3CA and JAK2 occurred in a small fraction of the Sarcomas and that these mutations may not play a principal role in the development of sarcomas.
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Comparative study of IDH 1 mutations in gliomas by immunohistochemistry and DNA sequencing
TLDR
IHC is an easy and quick method of detecting IDH1-R132H mutations, but there may be some discrepancies between IHC and DNA sequencing, so cross-reactivity and staining heterogeneity may have bearing over its use in detectingIDH1R 132H mutation in gliomas.
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
TLDR
IHC is an easy and quick method of detecting IDH1-R132H mutations, but there may be some discrepancies between IHC and DNA sequencing.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
TLDR
It is concluded that in tumors with an oligodendroglioma-like morphology, binding of H09 is highly specific for oligodendedrogliomas or oligoastrocytomas and substantially helps in the discrimination from other clear cell tumors.
Detection of 2‐Hydroxyglutarate in Formalin‐Fixed Paraffin‐Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry
TLDR
A method to detect 2HG levels in archival formalin‐fixed paraffin‐embedded tumor specimens by stable isotope dilution using gas chromatography followed by mass spectrometry (GC/MS).
...
1
2
...

References

SHOWING 1-10 OF 25 REFERENCES
Monoclonal antibody specific for IDH1 R132H mutation
TLDR
A mouse monoclonal antibody targeting the IDH1 R132H mutation is developed and shown the high specificity and sensitivity of this antibody on Western blots and tissue sections from formalin fixed paraffin embedded tumor specimens.
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
TLDR
Despite the infrequent incidence of the IDH1 mutations in prostate cancers and B‐ALL, mutated IDH 1 could be therapeutically targeted in these cancers and in glial tumors with the IDh1 mutations.
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
TLDR
Investigation of the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry finds the ability of mIDH1R132H to detect single infiltrating tumor cells intriguing.
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes
Differentiation of gliomas and reactive gliosis may be challenging both at primary tumor occurrence and at posttherapy biopsy. The most frequent IDH1 mutation found in the majority of WHO grade II…
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
TLDR
The data indicate that IDH1 mutation combined with either TP53 mutation or total 1p/19q loss is a frequent and early change in the majority of oligodendroglial tumors, diffuse astrocytomas, anaplastic astro CYTomas, and secondary glioblastomas but not in primary gliOBlastomas.
IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors
TLDR
The data indicate that cancer mutations affecting IDH1R132 are tissue‐specific, and suggest that it plays a unique role in the development of high‐grade gliomas.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
TLDR
An inverse association of IDH1 and IDH2 mutations of the R132C type are strongly associated with astrocytoma, while IDH 2 mutations predominantly occur in oligodendroglial tumors.
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
TLDR
It is concluded that IDH1 is associated with distinct clinical and biologic characteristics and seems to be very stable during disease evolution.
...
1
2
3
...